GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Mixed data results for two Monte Rosa molecular glue degraders [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $10.00. They now have an "equal weight" rating on the stock.
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $19.00 price target on the stock.
Form EFFECT Monte Rosa Therapeutics,
Form 4 Monte Rosa Therapeutics, For: Mar 24 Filed by: Leo Chandra P.
Form S-3 Monte Rosa Therapeutics,
Form S-8 Monte Rosa Therapeutics,
Form 10-K Monte Rosa Therapeutics, For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.